Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
5 Dividend King Stocks Gurus Are Feasting On
12:21pm, Tuesday, 31'st Jan 2023
According to the All-in-one Screener, a Premium feature of GuruFocus, five dividend kings stocks that have high guru ownership as of the third-quarter 2022 13F portfolio filings are Johnson & Johnson
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
12:12pm, Tuesday, 31'st Jan 2023
AbbVie's two-decade Humira monopoly came to an end Tuesday after Amgen launched its biosimilar copy. But AbbVie stock was mostly unmoved.
These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts
11:47am, Tuesday, 31'st Jan 2023 Benzinga
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
AbbVie (ABBV) Stock Moves -0.43%: What You Should Know
10:45pm, Monday, 30'th Jan 2023 Zacks Investment Research
AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day.
Down 14.5%, Is Pfizer Stock a Screaming Buy?
09:00pm, Monday, 30'th Jan 2023 The Motley Fool
Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock.
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
03:11pm, Monday, 30'th Jan 2023 Zacks Investment Research
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
02:10pm, Monday, 30'th Jan 2023 Zacks Investment Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of inco
S&P Global, AbbVie, And This Big 3 Automaker On CNBC's 'Final Trades'
01:24pm, Monday, 30'th Jan 2023 Benzinga
On CNBC’s "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management said S&P Global Inc. (NYSE: SPGI) went through a lot during the past few years. It was a "very hot stock" movin
AbbVie: Why The Company Is Still Overvalued
05:42am, Sunday, 29'th Jan 2023
According to the financial report of Johnson & Johnson, a partner of AbbVie, sales of Imbruvica decreased in the 4th quarter of 2022 due to increased competition. In less than six months, Humira's bio
7 Dividend Stocks to Buy Now or You'll Be Kicking Yourself Later
01:12pm, Saturday, 28'th Jan 2023
The recent rally in equities may be prying some cash off the sidelines. But if you're investing in pure growth stocks and avoiding dividend stocks altogether, I'd urge caution.
2 of the Best Dividend Stocks to Own in 2023
10:30am, Saturday, 28'th Jan 2023 The Motley Fool
You can count on them for passive income and growth over time.
The 4% DGI Core Portfolio: 2022 Year-End Review
09:00am, Saturday, 28'th Jan 2023
We present the 2022 year-end review of our eight-year-old Passive DGI-Core Portfolio. We consider this portfolio and strategy as the foundation of our overall portfolio. We will provide updates on cha
Final Trades: Abbvie, S&P Global and more
03:19pm, Friday, 27'th Jan 2023
The "Halftime Report" traders give their top picks to watch for the second half.
February Dividend Kings: 5 Buys; 1 To Watch
03:13pm, Friday, 27'th Jan 2023
"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the
5 Cheapest Health Care Stocks You Should Think About
01:48pm, Friday, 27'th Jan 2023 Benzinga
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock's strength on days when prices go
